JPH0751362A - Hemo-dialyzer - Google Patents
Hemo-dialyzerInfo
- Publication number
- JPH0751362A JPH0751362A JP20601393A JP20601393A JPH0751362A JP H0751362 A JPH0751362 A JP H0751362A JP 20601393 A JP20601393 A JP 20601393A JP 20601393 A JP20601393 A JP 20601393A JP H0751362 A JPH0751362 A JP H0751362A
- Authority
- JP
- Japan
- Prior art keywords
- hollow fiber
- cellulose diacetate
- cellulose
- pressure steam
- fiber membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012528 membrane Substances 0.000 claims abstract description 36
- 239000012510 hollow fiber Substances 0.000 claims abstract description 27
- 229920001747 Cellulose diacetate Polymers 0.000 claims abstract description 23
- 229920002284 Cellulose triacetate Polymers 0.000 claims abstract description 19
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 claims abstract description 19
- 102000009027 Albumins Human genes 0.000 claims abstract description 10
- 108010088751 Albumins Proteins 0.000 claims abstract description 10
- 102000036675 Myoglobin Human genes 0.000 claims abstract description 10
- 108010062374 Myoglobin Proteins 0.000 claims abstract description 10
- 238000007873 sieving Methods 0.000 claims description 16
- 230000001954 sterilising effect Effects 0.000 abstract description 21
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 21
- 239000008280 blood Substances 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract description 7
- 239000006185 dispersion Substances 0.000 abstract description 4
- 238000010411 cooking Methods 0.000 abstract 2
- 238000012216 screening Methods 0.000 abstract 2
- 239000000047 product Substances 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 9
- 230000015271 coagulation Effects 0.000 description 7
- 238000005345 coagulation Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 4
- 238000009987 spinning Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 239000003206 sterilizing agent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WSSSPWUEQFSQQG-UHFFFAOYSA-N 4-methyl-1-pentene Chemical compound CC(C)CC=C WSSSPWUEQFSQQG-UHFFFAOYSA-N 0.000 description 1
- 206010064553 Dialysis amyloidosis Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920002285 poly(styrene-co-acrylonitrile) Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920005668 polycarbonate resin Polymers 0.000 description 1
- 239000004431 polycarbonate resin Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、特に人工腎臓等に代表
される滅菌した血液透析器に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a sterilized hemodialyzer represented by an artificial kidney.
【0002】[0002]
【従来の技術】人体の臓器の機能を代行または補完する
ものとして、人工臓器の発達は著しく、とりわけ人工腎
臓が広く普及してきている。人工腎臓は血液中過剰水の
限外濾過と老廃物の除去をもって生体腎機能を代行する
ものである。この人工腎臓は最終工程で滅菌を施さなけ
ればならないが、従来の滅菌法としては、ホルマリンや
エチレンオキサイドガスを用いる方法があった。しかし
ながら、これらの方法は滅菌剤を使用するために微量の
残量が安全上問題となっていた。2. Description of the Related Art Artificial organs have been remarkably developed as a substitute or complement for the functions of human organs, and artificial kidneys have been widely spread. The artificial kidney substitutes the function of living kidney by ultrafiltration of excess water in blood and removal of waste products. This artificial kidney must be sterilized in the final step, but as a conventional sterilization method, there has been a method using formalin or ethylene oxide gas. However, since these methods use a sterilizing agent, a small amount of residual amount poses a safety problem.
【0003】滅菌剤を使用しない滅菌法としては、放射
線を用いる方法がある。これは人工腎臓に0.5〜5メ
ガラッドのγ線を照射するため、残留毒性の心配は無い
が、人工腎臓の部材とりわけ透析膜の劣下が著しく、溶
出物が発生する問題があった。また、大がかりな装置を
必要とする難点もあった。As a sterilization method that does not use a sterilizing agent, there is a method using radiation. Since the artificial kidney is irradiated with γ-rays of 0.5 to 5 megarads, there is no concern about residual toxicity, but there is a problem that the components of the artificial kidney, especially the dialysis membrane, are significantly deteriorated and an eluate is generated. Further, there is a drawback that a large-scale device is required.
【0004】これらの方法に対して、熱による滅菌とし
て高圧蒸気滅菌がある。これは通常115〜121℃の
飽和蒸気雰囲気下で約20〜30分間処理をするため、
残留毒性がない利点を有する。しかしながら、血液浄化
膜を構成する部材類の耐熱性や半透膜の熱劣下について
十分注意する必要があり、現実には、耐熱性素材の選
択、半透膜の熱劣下の小さい、膜素材の限られた組み合
わせにのみおいて実用化されている。現在、人工腎臓に
代表される血液浄化膜に用いられる半透膜の素材として
は、セルロースジアセテート膜、セルローストリアセテ
ート膜があるが、従来からこれらのセルロースアセテー
ト系膜は高圧蒸気滅菌すると基本性能を維持出来なかっ
た。In contrast to these methods, there is high-pressure steam sterilization as heat sterilization. This is usually performed in a saturated steam atmosphere at 115 to 121 ° C. for about 20 to 30 minutes,
It has the advantage of no residual toxicity. However, it is necessary to pay sufficient attention to the heat resistance of the materials that make up the blood purification membrane and the heat inferiority of the semipermeable membrane. It has been put to practical use only in a limited combination of materials. At present, there are cellulose diacetate membranes and cellulose triacetate membranes as materials for semipermeable membranes used in blood purification membranes typified by artificial kidneys. Conventionally, these cellulose acetate membranes have the basic performance when sterilized by high pressure steam. I couldn't keep up.
【0005】[0005]
【発明が解決しようとする課題】これらの問題を解決す
るために、本発明者らは鋭意研究を重ねた結果、セルロ
ーストリアセテートとセルロースジアセテートの混合品
からなる中空糸膜を用いれば、高圧蒸気滅菌後も基本性
能を維持することを見いだし、本発明を完成するに至っ
た。In order to solve these problems, the inventors of the present invention have made extensive studies and as a result, as a result of using a hollow fiber membrane composed of a mixture of cellulose triacetate and cellulose diacetate, high pressure steam is obtained. They found that the basic performance was maintained even after sterilization, and completed the present invention.
【0006】[0006]
【問題点を解決するための手段】即ち本発明は、セルロ
ーストリアセテート及びセルロースジアセテートが均一
に混合分散している素材から構成され、セルロースジア
セテートの重量百分率が1〜50重量%の範囲にあり、
121℃、20分間高圧蒸気処理後のアルブミンの篩い
係数が0.1以下であり且つミオグロビンの篩い係数が
0.1以上である中空糸膜が入口と出口を有する容器に
収納されてなる血液透析器に関するものである。That is, the present invention comprises a material in which cellulose triacetate and cellulose diacetate are uniformly mixed and dispersed, and the weight percentage of cellulose diacetate is in the range of 1 to 50% by weight. ,
Hemodialysis in which a hollow fiber membrane having a sieving coefficient of albumin of 0.1 or less and a sieving coefficient of myoglobin after high-pressure steam treatment at 121 ° C. for 20 minutes is 0.1 or more is housed in a container having an inlet and an outlet. It is related to vessels.
【0007】本発明に使用するセルロースジアセテート
とは、酢化度が52〜58重量%の範囲にあるものであ
り、またセルローストリアセテートとは酢化度が60〜
62重量%の範囲にあるものを意味する。ここで言う酢
化度とは以下の式で表されるものである。 酢化度(%)=(アセチル基の酢酸換算質量/全体質
量)×100The cellulose diacetate used in the present invention has an acetylation degree of 52 to 58% by weight, and cellulose triacetate has an acetylation degree of 60 to 60% by weight.
Means in the range of 62% by weight. The degree of acetylation here is represented by the following formula. Acetification degree (%) = (acetic acid equivalent mass of acetyl group / total mass) x 100
【0008】本発明に係わる高圧蒸気滅菌可能な中空糸
膜は例えば次のようにして製造される。即ち、紡糸原液
中のセルローストリアセテート及びセルロースジアセテ
ートの合計濃度を10重量%以上とし、かつ150℃以
上の沸点を有する非プロトン性極性溶媒及び非溶媒を使
用して作製した紡糸原液を二重管ノズルより吐出する。
この吐出に際して、吐出温度(T1)と凝固浴温度(T
2)の関係を0<T1−T2≦100(℃)に制御する
ことが重要である。凝固浴は上記溶媒と非溶媒の水溶液
を用いる。非プロトン性極性溶媒としては、N−メチル
ピロリドン、ジメチルホルムアミド、ジメチルアセトア
ミド、ジメチルスルホキシド等が、非溶媒としてはエチ
レングリコール、トリエチレングリコール、ポリエチレ
ングリコール、グリセリン、ポリプロピレングリコール
等の多価アルコールやメタノ−ル、エタノール等のアル
コール類等が使用できる。また、この中空糸膜は凝固
浴、水洗浴を経て親水化浴にて親水化する。親水化剤と
しては、グリセリン、ポリエチレングリコール等の多価
アルコールの他、メタノ−ル、エタノール等のアルコー
ル類が使用できる。さらに中空糸膜は乾燥工程を通り巻
取られる。The high-pressure steam sterilizable hollow fiber membrane according to the present invention is manufactured, for example, as follows. That is, the total concentration of cellulose triacetate and cellulose diacetate in the spinning dope is 10% by weight or more, and an aprotic polar solvent having a boiling point of 150 ° C. or more and a spinning dope prepared by using a non-solvent are prepared in a double tube. Discharge from the nozzle.
During this discharge, the discharge temperature (T1) and the coagulation bath temperature (T
It is important to control the relationship of 2) to 0 <T1-T2 ≦ 100 (° C.). The coagulation bath uses an aqueous solution of the above solvent and non-solvent. As the aprotic polar solvent, N-methylpyrrolidone, dimethylformamide, dimethylacetamide, dimethylsulfoxide and the like, and as the non-solvent, polyhydric alcohol such as ethylene glycol, triethylene glycol, polyethylene glycol, glycerin, polypropylene glycol and methano-. Alcohols such as alcohol and ethanol can be used. The hollow fiber membrane is hydrophilized in a hydrophilization bath after passing through a coagulation bath and a washing bath. As the hydrophilizing agent, polyhydric alcohols such as glycerin and polyethylene glycol as well as alcohols such as methanol and ethanol can be used. Further, the hollow fiber membrane is wound up through a drying process.
【0009】本発明に使用される中空糸膜は、セルロー
ストリアセテートとセルロースジアセテートが均一に混
合分散している素材から構成されていることを特徴とす
る。セルローストリアセテート中空糸膜に熱処理を行う
と結晶化が進行し、糸長方向及び半径方向に収縮し、著
しく性能が低下してしまう。またセルロースジアセテー
トに中空糸膜においては配向により糸長方向に伸長す
る。従ってセルローストリアセテートにセルロースジア
セテートを混合することによりセルローストリアセテー
トの結晶を抑え、さらには収縮も抑えることが出来、高
圧蒸気滅菌後、初期の性能を保持することができる。The hollow fiber membrane used in the present invention is characterized by being made of a material in which cellulose triacetate and cellulose diacetate are uniformly mixed and dispersed. When heat treatment is applied to the cellulose triacetate hollow fiber membrane, crystallization progresses, shrinks in the yarn length direction and the radial direction, and the performance remarkably decreases. In the hollow fiber membrane, cellulose diacetate is stretched in the yarn length direction due to orientation. Therefore, by mixing cellulose triacetate with cellulose diacetate, it is possible to suppress the crystals of cellulose triacetate and further suppress the shrinkage, and it is possible to maintain the initial performance after high-pressure steam sterilization.
【0010】また、混合時のセルロースジアセテートの
重量百分率は1〜50%、望ましくは5〜45%であ
る。これはセルロースジアセテートが1%未満では高圧
蒸気滅菌後のアルブミンの篩い係数が大きくなりすぎる
ためであり、また逆にセルロースジアセテート50%以
上では高圧蒸気滅菌後のミオグロビンの篩い係数が0.
5を越えるのが難しいためである。The weight percentage of cellulose diacetate at the time of mixing is 1 to 50%, preferably 5 to 45%. This is because when the cellulose diacetate is less than 1%, the sieving coefficient of albumin after autoclaving becomes too large, and conversely, when the cellulose diacetate is 50% or more, the sieving coefficient of myoglobin after autoclaving is 0.
It is difficult to exceed 5.
【0011】次に本発明に使用される中空糸膜は121
℃、20分間高圧蒸気処理後のアルブミンの篩い係数が
0.1以下であり且つミオグロビンの篩い係数が0.1
以上なければならない。アルブミンの篩い係数が0.1
以上ある中空糸膜またはミオグロビンの篩い係数が0.
5以上の中空糸膜は、紡糸原液組成、凝固条件等により
製造することは可能である。しかし、アルブミンの篩い
係数が0.1以上の場合には高圧蒸気滅菌により篩い係
数が大きくなりすぎ有用なアルブミンの大量リークにつ
ながる。またミオグロビンの篩係数が0.1以下では高
圧蒸気滅菌後の篩い係数が0.5を越えず、透析アミロ
イドーシスの原因物質であるβ2ミクログロブリンのよ
うな中分子量物質の除去が困難となる。なお、ここでア
ルブミン並びにミオグロビンの篩い係数SCは、次式で
定義されるものである。 SC=2Cfil/(Cin+Cout) ここで、 Cfil:濾過液濃度 Cin :入口液濃度 Cout:出口液濃度 である。Next, the hollow fiber membrane used in the present invention is 121
The sieving coefficient of albumin after high-pressure steam treatment at 20 ° C. for 20 minutes is 0.1 or less, and the sieving coefficient of myoglobin is 0.1.
There must be more. The sieving coefficient of albumin is 0.1
The sieving coefficient of the above hollow fiber membrane or myoglobin is 0.
Hollow fiber membranes of 5 or more can be produced depending on the spinning dope composition, coagulation conditions and the like. However, when the sieving coefficient of albumin is 0.1 or more, the sieving coefficient becomes too large due to high-pressure steam sterilization, which leads to a large leak of useful albumin. When the sieving coefficient of myoglobin is 0.1 or less, the sieving coefficient after high-pressure steam sterilization does not exceed 0.5, which makes it difficult to remove a medium molecular weight substance such as β2 microglobulin which is a causative substance of dialysis amyloidosis. The sieving coefficient SC of albumin and myoglobin is defined by the following equation. SC = 2 Cfil / (Cin + Cout) where Cfil: filtrate concentration Cin: inlet liquid concentration Cout: outlet liquid concentration.
【0012】本発明に係わる中空糸膜を入口と出口を有
する容器に収納し血液浄化用透析器に組立て、公知の高
圧蒸気滅菌を行うのであるが、その温度は80〜140
℃が好ましい。80℃以下では滅菌状態が完全でなく、
また140℃以上では中空糸膜の性能低下が著しいばか
りでなく、透析器に使用される部材の劣下が激しく、事
実上実用に供するものを製造するのが難しい。以上より
本発明による血液浄化用透析器は80℃から140℃の
範囲の滅菌処理をする必要がある。特に望ましくは11
5℃の30分間または121℃で20分間、126℃で
15分間蒸気滅菌するのがよい。The hollow fiber membrane according to the present invention is housed in a container having an inlet and an outlet and assembled in a blood purification dialyzer to perform known high-pressure steam sterilization at a temperature of 80 to 140.
C is preferred. Sterilization is not perfect below 80 ° C,
Further, at 140 ° C. or higher, not only the performance of the hollow fiber membrane is significantly deteriorated, but also the members used in the dialyzer are severely deteriorated, and it is practically difficult to manufacture a practical product. From the above, the blood purification dialyzer according to the present invention needs to be sterilized in the range of 80 ° C to 140 ° C. Particularly desirable is 11
Steam sterilization at 5 ° C. for 30 minutes, 121 ° C. for 20 minutes, or 126 ° C. for 15 minutes is preferable.
【0013】本発明に使用される中空糸膜を収納する容
器は80℃近辺の加熱に対してはスチレン−アクリロニ
トリルコポリマー樹脂製、それ以上の温度においてはポ
リカーボネイト、ポリ−4−メチルペンテン−1樹脂製
等が使用され得る。本発明により製造された滅菌された
血液浄化用透析器は無菌状態にあり、また残留毒性の危
険がなく、透析性能が十分高いという利点を有し、人工
透析等の治療においてその効果を大いに発揮し得るもの
を提供することができる。The container for accommodating the hollow fiber membrane used in the present invention is made of styrene-acrylonitrile copolymer resin for heating at around 80 ° C., and at higher temperatures, polycarbonate, poly-4-methylpentene-1 resin. Manufacturing etc. can be used. The sterilized blood purification dialyzer manufactured by the present invention has the advantages that it is in a sterile state, there is no risk of residual toxicity, and the dialysis performance is sufficiently high, and its effect is greatly exerted in the treatment such as artificial dialysis. What can be done can be provided.
【0014】また、本発明の血液浄化用透析器は人工腎
臓に限定されず、人工肺、人工肝臓、人工膵臓等にも十
分応用できるものである。以下、実施例及び比較例を用
いて本発明を更に詳細に説明する。The blood purification dialyzer of the present invention is not limited to artificial kidneys, but can be applied to artificial lungs, artificial livers, artificial pancreas and the like. Hereinafter, the present invention will be described in more detail with reference to Examples and Comparative Examples.
【0015】実施例1 セルローストリアセテート/セルロースジアセテート=
90/10の混合品を20重量%、N−メチルピロリド
ン64重量%、トリエチレングリコール16重量%の紡
糸原液を調製した。これを二重管ノズルより吐出し、凝
固浴に導いた。吐出温度は130℃で、凝固浴温度は5
0℃であった。また凝固浴はN−メチルピロリドン24
重量%、トリエチレングリコール6重量%の水溶液を使
用した。この後、中空糸膜は約50℃の水洗浴を、約5
0℃、約50%のグリセリン親水化浴、約100℃の乾
燥工程を経て巻取られる。得られた中空糸膜の内径は約
200μm、膜厚は約15μmであった。この中空糸膜
を800本、約25cmの長に切断し、ポリカーボネー
ト樹脂製の容器に収納して初期透過性能、121℃で2
0分の高圧蒸気滅菌後の透過性能及び性能保持率を測定
した。その結果を表1に示す。Example 1 Cellulose triacetate / cellulose diacetate =
A spinning dope containing 20% by weight of the mixture of 90/10, 64% by weight of N-methylpyrrolidone and 16% by weight of triethylene glycol was prepared. This was discharged from a double tube nozzle and led to a coagulation bath. Discharge temperature is 130 ° C, coagulation bath temperature is 5
It was 0 ° C. The coagulation bath is N-methylpyrrolidone 24
An aqueous solution containing 6% by weight of triethylene glycol was used. After that, the hollow fiber membrane was washed with a washing bath at about 50 ° C for about 5 minutes.
It is wound up through a drying process at 0 ° C. and about 50% glycerin hydrophilization bath at about 100 ° C. The hollow fiber membrane thus obtained had an inner diameter of about 200 μm and a membrane thickness of about 15 μm. 800 pieces of this hollow fiber membrane were cut into a length of about 25 cm, stored in a container made of polycarbonate resin, and the initial permeation performance was 2 at 121 ° C.
The permeation performance and performance retention after high-pressure steam sterilization for 0 minutes were measured. The results are shown in Table 1.
【0016】表1によれば、本発明の実施例では高圧蒸
気滅菌後の透過係数の保持率も高く、十分実用に供し得
る製品を得ることができる。また製品間の性能のバラツ
キも小さく、さらに滅菌後無菌テストにより製品に菌を
検出することはできなかった。According to Table 1, in the examples of the present invention, the retention rate of the permeability coefficient after high-pressure steam sterilization is high, and a product that can be sufficiently put into practical use can be obtained. In addition, variations in performance among products were small, and it was not possible to detect bacteria in the products by a sterilization test after sterilization.
【0017】実施例2 セルローストリアセテート/セルロースジアセテート=
80/20の混合品による中空糸膜を実施例1と同様の
条件で製造した。得られた中空糸膜の性能結果を表1に
示す。実施例1と同様、十分実用に供し得る製品を得る
ことができ、また製品に菌を検出することはできなかっ
た。Example 2 Cellulose triacetate / cellulose diacetate =
A hollow fiber membrane made of an 80/20 mixture was manufactured under the same conditions as in Example 1. Table 1 shows the performance results of the obtained hollow fiber membranes. As in Example 1, a product that could be put to practical use could be obtained, and no fungus could be detected in the product.
【0018】実施例3 セルローストリアセテート/セルロースジアセテート=
70/30の混合品による中空糸膜を実施例1と同様の
条件で製造した。得られた中空糸膜の性能結果を表1に
示す。実施例1、2と同様、十分実用に供し得る製品を
得ることができ、また製品に菌を検出することはできな
かった。Example 3 Cellulose triacetate / cellulose diacetate =
A hollow fiber membrane made of a 70/30 mixture was manufactured under the same conditions as in Example 1. Table 1 shows the performance results of the obtained hollow fiber membranes. As in Examples 1 and 2, it was possible to obtain a product that could be sufficiently put to practical use, and it was not possible to detect bacteria in the product.
【0019】比較例1 セルローストリアセテート単品を用いて、実施例と同様
にして中空糸膜を製造した。得られた中空膜の初期透過
性能、121℃で20分の高圧蒸気滅菌後の透過性能及
び性能保持率を表1に示す。セルローストリアセテート
単品では、初期の透過係数は80×10-5cm/sec以上あ
るが、高圧蒸気滅菌後の保持率が低くまたバラツキも大
きいため実用的ではなかった。Comparative Example 1 A hollow fiber membrane was produced in the same manner as in Example 1, except that cellulose triacetate was used alone. Table 1 shows the initial permeation performance, the permeation performance after high-pressure steam sterilization at 121 ° C. for 20 minutes, and the performance retention rate of the obtained hollow membrane. Cellulose triacetate alone has an initial permeability coefficient of 80 × 10 −5 cm / sec or more, but it is not practical because the retention rate after high-pressure steam sterilization is low and the dispersion is large.
【0020】比較例2 セルローストリアセテート/セルロースジアセテート=
40/60の混合品を用いて、実施例と同様にして中空
糸膜を製造した。得られた中空膜の初期透過性能、12
1℃で20分の高圧蒸気滅菌後の透過性能及び性能保持
率を表1に示す。セルローストリアセテート/セルロー
スジアセテート=40/60の混合品では、高圧蒸気滅
菌後のミオグロビンの篩い係数が低く、これも実用的で
はなかった。Comparative Example 2 Cellulose triacetate / cellulose diacetate =
A 40/60 mixture was used to manufacture a hollow fiber membrane in the same manner as in the example. Initial permeability of the obtained hollow membrane, 12
Table 1 shows the permeation performance and performance retention after high-pressure steam sterilization at 1 ° C. for 20 minutes. The mixture of cellulose triacetate / cellulose diacetate = 40/60 had a low sieving coefficient of myoglobin after high-pressure steam sterilization, which was also not practical.
【0021】[0021]
【表1】 [Table 1]
【0022】[0022]
【発明の効果】本発明による方法によって得られた血液
浄化用透析器は高圧蒸気滅菌による性能低下及びそのバ
ラツキが小さく、また十分滅菌された製品の提供を可能
にする。EFFECTS OF THE INVENTION The blood purification dialyzer obtained by the method according to the present invention has little deterioration in performance due to high-pressure steam sterilization and its variation, and it is possible to provide a sufficiently sterilized product.
Claims (1)
スジアセテートが均一に混合分散している素材から構成
され、セルロースジアセテートの重量百分率が1〜50
重量%の範囲にあり、121℃、20分間高圧蒸気処理
後のアルブミンの篩い係数が0.1以下であり且つミオ
グロビンの篩い係数が0.1以上である中空糸膜が入口
と出口を有する容器に収納されてなる血液透析器。1. Cellulose triacetate and cellulose diacetate are uniformly mixed and dispersed, and the weight percentage of cellulose diacetate is 1 to 50.
A container having a hollow fiber membrane having an inlet and an outlet having a sieving coefficient of 0.1 or less for albumin after high-pressure steam treatment at 121 ° C. for 20 minutes and a sieving coefficient of myoglobin of 0.1 or more in the range of wt%. A hemodialyzer stored in the.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20601393A JPH0751362A (en) | 1993-08-20 | 1993-08-20 | Hemo-dialyzer |
| US08/272,397 US5624561A (en) | 1993-07-28 | 1994-07-26 | Cellulose acetate hemodialysis membrane |
| EP94111598A EP0636403A3 (en) | 1993-07-28 | 1994-07-26 | Cellulose acetate hemodialysis membrane. |
| CA002129089A CA2129089A1 (en) | 1993-07-28 | 1994-07-28 | Cellulose acetate hemodialysis membrane |
| US08/730,599 US5783124A (en) | 1993-07-28 | 1996-10-15 | Cellulose acetate hemodialysis membrane |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20601393A JPH0751362A (en) | 1993-08-20 | 1993-08-20 | Hemo-dialyzer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0751362A true JPH0751362A (en) | 1995-02-28 |
Family
ID=16516467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP20601393A Pending JPH0751362A (en) | 1993-07-28 | 1993-08-20 | Hemo-dialyzer |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0751362A (en) |
-
1993
- 1993-08-20 JP JP20601393A patent/JPH0751362A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4848278B2 (en) | Highly permeable hollow fiber membrane blood purifier and method for producing the same | |
| EP1410839B1 (en) | Hollow fiber membrane for purifying blood | |
| JP3636199B1 (en) | Polysulfone-based permselective hollow fiber membrane bundle, method for producing the same and blood purifier | |
| JPS59211459A (en) | Pasturization of blood treating device | |
| EP0012630B1 (en) | Process for producing a cellulose acetate-type permselective membrane, permselective membrane thus produced, and use of such membrane in artificial kidney | |
| JPWO2000027447A1 (en) | blood purifier | |
| JP3928910B2 (en) | Polysulfone blood treatment module | |
| GB1567133A (en) | Sterilization of membranes | |
| JPS5938805B2 (en) | Manufacturing method of semipermeable membrane with selective permselectivity | |
| US4886631A (en) | Cellulose ester hollow fiber membrane for plasma separation | |
| JP4352709B2 (en) | Polysulfone-based semipermeable membrane and artificial kidney using the same | |
| JPH0751362A (en) | Hemo-dialyzer | |
| JPH05228208A (en) | Cellulose acetate base blood purifying hollow thread membrane and its manufacture | |
| JPS6213022B2 (en) | ||
| JP4129393B2 (en) | Extracorporeal treatment apparatus for blood or plasma containing wet semipermeable membrane and method for producing the same | |
| JPH0970431A (en) | Method for producing polysulfone hollow fiber type artificial kidney and artificial kidney | |
| JP2001038170A (en) | Hollow fiber membrane | |
| JP3334705B2 (en) | Polysulfone-based selectively permeable hollow fiber membrane | |
| JP2779257B2 (en) | Blood processing equipment sterilization method | |
| JPS6411322B2 (en) | ||
| JP4501155B2 (en) | Method for producing polysulfone-based permselective hollow fiber membrane bundle | |
| JP4748348B2 (en) | Polysulfone-based permselective hollow fiber membrane bundle | |
| JP4622015B2 (en) | Module incorporating a membrane and manufacturing method thereof | |
| JPH0362447B2 (en) | ||
| JPH10174850A (en) | Processing method of hollow fiber membrane |